The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery Contract (IDC) to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of up to 23 standard pediatric vaccines. The $3.301 billion contract will run from April 1, 2022 through March 31, 2023, supporting the CDC's Immunization Awardees and the Vaccines for Children program under Section 317(j) of the Public Health Service Act.
The vaccines being procured include a wide range such as DTaP, Hep A, Hep B, Hib, HPV, MMR, MCV4, and Varicella, among others. Merck will be required to provide vaccines with a minimum 12-month shelf life and meet specified dose quantities, from minimums of 100 doses up to maximums ranging from 350,000 to 13 million doses per vaccine. The contract is structured as a multiple award vehicle, with vaccines to be shipped FOB Destination to the 50 U.S. states and territories. This acquisition was conducted under FAR Part 12, Acquisition of Commercial Items, and does not involve any set-aside designations.
Generated 1/1/25, 12:09 AM